X0202 SCHEDULE 13D/A 0001104659-25-114697 0001900201 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 07/30/2026 false 0001770069 56565P103 MapLight Therapeutics, Inc.

800 Chesapeake Drive Redwood City CA 94063

Robert Brown (650) 812-2614 c/o Catalyst4, Inc. 555 Bryant Street #376 Palo Alto CA 94301 Kenneth A, Clark 650-493-9300 Wilson Sonsini Goodrich & Rosati, P.C. 650 Page Mill Road Palo Alto CA 94304 0001900201 N Catalyst4, Inc. WC N DE 20906689.00 0.00 20906689.00 0.00 20906689.00 N 47.9 CO *The percent of class calculation is based on 43,647,188 shares of voting common stock of the Issuer outstanding as of July 27, 2026. Y Robert Brown AF N X1 0.00 20906689.00 0.00 20906689.00 20906689.00 N 47.9 IN *The percent of class calculation is based on 43,647,188 shares of voting common stock of the Issuer outstanding as of July 27, 2026. Y Ekemini Riley AF N X1 0.00 20906689.00 0.00 20906689.00 20906689.00 N 47.9 IN *The percent of class calculation is based on 43,647,188 shares of voting common stock of the Issuer outstanding as of July 27, 2026. Y Mark Vorsatz AF N X1 0.00 20906689.00 0.00 20906689.00 20906689.00 N 47.9 IN *The percent of class calculation is based on 43,647,188 shares of voting common stock of the Issuer outstanding as of July 27, 2026. Common Stock, $0.0001 par value per share MapLight Therapeutics, Inc. 800 Chesapeake Drive Redwood City CA 94063 This Amendment No 1 to the Schedule 13D filed by the undersigned on November 20, 2025, is hereby filed to update certain information with respect to the beneficial ownership of Voting Common Stock (the "Shares") of MapLight Therapeutics, Inc., a Delaware company (the "Issuer"), by Catalyst4, Inc. ("Catalyst"), Robert Brown, Ekemini Riley and Mark Vorsatz. The foregoing individuals, together with Catalyst, are collectively referred to as the "Reporting Persons." Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following information: During the last 60 days, the Reporting Persons acquired 1,209,225 Shares of the Issuer in multiple open market transactions for an aggregate purchase price of approximately $15.3 million, including commissions, as further disclosed in Item 5(c) of this Schedule 13D, which is incorporated by reference herein. The source of funds for the purchase of such Shares of the Issuer was the working capital of Catalyst. No part of the purchase price was represented by borrowed funds or other consideration obtained for the purpose of acquiring, holding, trading, or voting the securities, and there were no loans or financing arrangements involved in the transaction, with no other parties providing funds or consideration. Item 5(c) of the Schedule 13D is hereby amended and supplemented by adding the following information: The transactions by the Reporting Persons in the Shares of the Issuer during the past 60 days are set forth in Annex A to this Schedule 13D. This Amendment is being filed because the additional purchases effected by the Reporting Person subsequent to the Schedule 13D filed by the Reporting Person on November 20, 2025 (the "Prior Filing"), represent a material increase to the Reporting Person's ownership percentage of the Issuer's outstanding Shares. The transactions set forth in Annex A include the additional purchases of Shares effected by Catalyst subsequent to the Prior Filing, which are identified in Annex A. The Reporting Persons note that such additional purchases were previously disclosed on a Form 4 filed by Catalyst with the Securities and Exchange Commission on July 30, 2026. Except as otherwise disclosed herein, the Reporting Persons have not effected any transaction in the Shares in the last 60 days. Annex A: Schedule of Transactions Catalyst4, Inc. /s/ Robert Brown 08/03/2026 Robert Brown /s/ Robert Brown 08/03/2026 Ekemini Riley /s/ Ekemini Riley 08/03/2026 Mark Vorsatz /s/ Mark Vorsatz 08/03/2026